• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

DL-Buthionine-(S,R)-sulfoximine and Its Significance in Modern Chemical Biology

The compound with the CAS number 5072-26-4 is known as DL-Buthionine-(S,R)-sulfoximine, a molecule that has garnered significant attention in the field of chemical biology due to its unique structural and functional properties. This compound, characterized by its sulfoximine moiety, plays a crucial role in various biological processes and has been extensively studied for its potential therapeutic applications.

DL-Buthionine-(S,R)-sulfoximine is an interesting derivative of buthionine, a well-known amino acid that is involved in numerous metabolic pathways. The sulfoximine group introduces a high degree of specificity to the molecule, making it a valuable tool in the development of targeted therapies. Recent studies have highlighted its role in modulating redox signaling pathways, which are critical for maintaining cellular homeostasis.

The structural uniqueness of DL-Buthionine-(S,R)-sulfoximine lies in its ability to interact with specific biological targets. This interaction is mediated by the sulfoximine group, which exhibits both electrophilic and nucleophilic characteristics, allowing it to participate in diverse chemical reactions within the cell. Such properties make it an attractive candidate for drug development, particularly in the context of diseases where redox imbalances are prevalent.

In recent years, research has focused on harnessing the potential of DL-Buthionine-(S,R)-sulfoximine in the treatment of various neurological and inflammatory disorders. Studies have demonstrated its ability to inhibit key enzymes involved in oxidative stress pathways, thereby protecting against neuronal damage. For instance, research published in leading journals has shown that this compound can attenuate neuroinflammation and reduce oxidative damage in models of Alzheimer's disease and Parkinson's disease.

The therapeutic potential of DL-Buthionine-(S,R)-sulfoximine extends beyond neurological disorders. Emerging evidence suggests that it may also play a role in combating cancer by modulating key signaling pathways that drive tumor growth. In preclinical studies, this compound has been shown to induce apoptosis in cancer cells while sparing healthy cells, making it a promising candidate for further clinical investigation.

The synthesis of DL-Buthionine-(S,R)-sulfoximine is a complex process that requires precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies have been developed to optimize this process, enabling the production of sufficient quantities for both research and clinical purposes. These methodologies often involve multi-step reactions and require careful optimization to achieve the desired stereoselectivity.

The pharmacokinetic properties of DL-Buthionine-(S,R)-sulfoximine are another area of active investigation. Understanding how this compound is absorbed, distributed, metabolized, and excreted is crucial for determining its therapeutic efficacy and safety profile. Studies have shown that it exhibits moderate bioavailability and a relatively long half-life, suggesting that it may be suitable for once-daily dosing regimens.

In conclusion, DL-Buthionine-(S,R)-sulfoximine, with its CAS number 5072-26-4, represents a significant advancement in the field of chemical biology. Its unique structure and functional properties make it a valuable tool for investigating various biological processes and developing new therapies. As research continues to uncover its potential applications, this compound is poised to play a crucial role in addressing some of the most challenging diseases faced by humanity today.

• 83730-53-4(L-Buthionine-(S,R)-sulfoximine)
• 5072-23-1(Butanoic acid, 2-amino-4-(S-ethylsulfonimidoyl)-)
• 83730-55-6(Butanoic acid,2-amino-4-(S-hexylsulfonimidoyl)-, (2R)- (9CI))
• 113158-69-3(Butanoic acid,2-amino-4-(S-butylsulfonimidoyl)-, [S-(R*,S*)]- (9CI))
• 15985-39-4(L-Methionine-DL-sulfoximine)
• 96304-91-5(Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, methyl ester)
• 127708-41-2(Butanoic acid,2-amino-4-[[S(R)]-S-butylsulfonimidoyl]-, (2S)-rel-)
• 1982-67-8(2-Amino-4-(S-methylsulfonimidoyl)butanoic Acid)
• 21752-31-8(L-Methionine R-Sulfoximine)
• 70085-86-8(Butanoic acid,2-amino-4-(S-propylsulfonimidoyl)- (9CI))